This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Warren E. Buffett, 2015
Bruner, Robert F.; DuBois, JakeCase DARDEN-F-1769-EFinanceThis case was designed as an introduction to a finance course or a module on capital markets. Alternatively, it could be used as a basic introduction to methods of valuing a firm. A detailed teaching note provides instructors with a teaching plan for either scenario. Set in August 2015, students are asked to evaluate Warren Buffett’s decision to acquire the aerospace-parts supplier Precision Castparts Corporation (PCP), which would be the largest...Starting at €8.20
-
Warren E. Buffett, 2015 - Teaching Note
Bruner, Robert F.Teaching Note DARDEN-F-1769TN-EFinanceTeaching note for product F-1769Starting at €0.00
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Genzyme/Geltex Pharmaceuticals Joint Venture
Bruner, Robert F.; Bodily, Samuel E.; Jacquet, PierreCase DARDEN-F-1254-EFinanceIn March 1997, an executive vice president of Genzyme Corporation must develop the terms by which the $518 billion (revenue) firm will form a joint venture with a small biotechnology firm to make and market a new drug. The tasks for the decision maker are to estimate the enterprise value of the new joint venture, recommend how large an interest to acquire in the venture, and determine what price to pay for that interest and when. The case may be ...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
The Wm. Wrigley Jr. Company: Capital Structure, Valuation, and Cost of Capital (Spanish version)
Bruner, Robert F.; Carr, SeanCase DARDEN-F-1840FinanceEsta es una traducción al español de la versión del 15 de noviembre de 2005 del caso UVA-F-1482. En junio de 2002, el director de un fondo de cobertura "el inversionista activo" está considerando las posibles ganancias de aumentar la capitalización de la deuda de The Wm. Wrigley Jr. Company. Wrigley ha sido financiado de manera conservadora y, a la fecha del caso, no tiene deudas. Las tareas para el estudiante son: • Estimar el cambio potencial e...Starting at €8.20
-
Poles apart on PZU (C)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCase HBS-912015-EAfter a decade-long dispute with the Polish State Treasury, in October 2009 the Dutch insurer Eureko agreed to exit PZU in exchange for compensation. Who was the biggest beneficiary of the settlement: Eureko, the Treasury, or PZU itself?Starting at €5.74
-
Veolia: Resourcing the World
Ahuja, Gautam; Khanna, Tarun; Maslauskaite, Kristina; Dessain, VincentCase HBS-717505-EStrategyA global environmental service provider goes through major changes to offer integrated solutions and reach out to new countries.Starting at €8.20
-
Ilva Steel Taranto: Providing and Polluting (C)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314059-EStarting at €5.74
-
BASF: Co-Creating Innovation (B)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCase HBS-517074-EMarketingSupplement to case 517073.Starting at €5.74